Nov 14, 2019 · EBV latent protein EBNA1, EBNA3C, LMP-1, and lytic proteins BZLF-1 can alter p53 expressions in many cancer cell lines. Interactions of p63 with EBNA-1, 2, 5, LMP-2A and BARF-1 have also been investigated in several cancers.

Antibodies to p53 were inversely associated with EBV positivity (3% vs. 15%; adjusted OR=0.16, p=0.021). Anti-p53 prevalence from the literature was 15%. These serological patterns suggest viral reactivation in EBV-positive cancers and identify variation of p53 seropositivity by subtype.

Oct 10, 2017 · EBV latent membrane protein 1 (LMP1) is required for the efficient transformation of primary B lymphocytes in vitro and possibly in vivo. The tumor suppressor p53 plays a seminal role in cancer development. In some EBV-associated cancers, p53 tends to be wild type and overly expressed; however, the effects of p53 on LMP1 expression is not clear.

Serum antibodies against four EBV proteins, nuclear (EBNA), viral capsid (VCA), early-diffuse (EA-D), and Zta replication activator (ZEBRA), and to p53 were assessed by multiplex assays. OR of antibody level tertiles (T1-T3) were adjusted by logistic regression.

Aug 31, 2020 · We found, unexpectedly, that HIF-1α-stabilizing drugs only induce reactivation when they also induce accumulation of phosphorylated, wild-type p53. Fortunately, p53 phosphorylation can also be provided by drugs such as nutlin-3, …

Feb 9, 2019 · EBV immediate-early protein BZLF1 (Z) is found to be interacting with the p53 through its C-terminus region and inhibits the p53 dependent transactivation in lymphoid cell, but overexpression of p53 restores its function (Zhang et al., 1994).

Nov 12, 2018 · BART5-3p is the first EBV-microRNA to be identified as inhibiting p53 expression and function, which suggests a novel mechanism underlying the strategies employed by EBV to maintain latent infection and promote the development of EBV-associated carcinomas.

In this review, we have surveyed and summarised the interactions of EBV gene products, known so far, with the p53 family proteins. The interactions between P53 and EBV oncoproteins are observed in stomach cancer, non-Hodgkin's lymphoma (NHL) of the head and neck, Nasopharyngeal Cancer (NPC), Gastric carcinoma (GC) and Burkitt's lymphoma (BL).

Apr 24, 2018 · In this study, we study the activity of p53 in immortalised nasopharyngeal epithelial cells using nutlin-3, an MDM2 antagonist. The impact of EBV infection on the protein expression of p53 and its ability to stimulate its transcriptional target genes is studied.

Antibodies to p53 were inversely associated with EBV positivity (3% vs. 15%; adjusted OR=0.16, p=0.021). Anti-p53 prevalence from the literature was 15%. These serological patterns suggest viral reactivation in EBV-positive cancers and identify variation of p53 seropositivity by subtype.